Premium
Antioxidant micronutrients and their performance in Hispanics infected with the human immunodeficiency virus and/or hepatitis C virus
Author(s) -
Yoon GA,
Beretta G,
Yeum KJ,
Forrester J E
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.542.1
Subject(s) - medicine , hepatitis c virus , hepatitis c , uric acid , micronutrient , insulin , diabetes mellitus , insulin resistance , endocrinology , immunology , virus , pathology
Antioxidant micronutrients and total antioxidant performance (TAP) were determined in Hispanics infected with HIV and/or hepatitis C (HCV). Hispanics > 18 yrs were stratified to 1) HIV alone (HIV, n=75), 2) HIV with HCV (HIV/HCV, n=115), 3) HCV alone (HCV, n=58), and 4) control (C, n=84). Plasma antioxidants were measured by HPLC‐UVD & ‐ECD, insulin sensitivity by Quantitative Insulin Sensitivity Check Index (QUICKI), and TAP by fluorometry. HIV and HIV/HCV showed higher plasma triglyceride & glucose, and lower QUICKI than C. Plasma insulin was significantly higher in HIV/HCV and higher tendency in HIV and HCV than that of C. Although antioxidant micronutrients were normal in range, significantly lower plasma carotenoid in HIV, HIV/HCV and HCV and of uric acid and vitamin E in HIV and HIV/HCV, respectively, than those of C were found. Uric acid and insulin were lowest in HIV and C, respectively, among groups. TAP was significantly higher in HIV/HCV and HCV (p<0.0001) than HIV or C. Multivariate regression analysis indicated that uric acid was a predictor of TAP in HIV, HIV/HCV and HCV and insulin in C. When insulin was excluded from the model, uric acid became a predictor of TAP in C. Thus, unexpectedly higher TAP in HIV/HCV and HCV may be due to uric acid and elevated insulin caused by endocrine‐metabolic disturbances. The significance of elevated TAP in the HIV/HCV and HCV warrants further study. (Supported by NIDA DA11598, DA14501, Ctr Metab Res on HIV & Drug Use P30DA013868)